EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Effect of Sacubitril/Valsartan on Supraventricular and Ventricular Arrhythmias in Patients With Heart Failure

Alireza Arzhangzadeh, Mohammad Hossein Nikoo, Majid Haghjoo iD, Fatemeh Rasekh, Shayan Shojaei iD, Asma Mousavi, Salma Nozhat, Roozbeh Narimani-Javid iD, Helia Bazroodi, Sana Neisi, Mitra Mojibpour, Mohammad Abedini und 3 weitere

Annals of Noninvasive Electrocardiology · 2025

DOI: 10.1111/anec.70081 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Noninvasive Electrocardiology, 2025. Verfasst von Alireza Arzhangzadeh und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Shiraz University of Medical Sciences, Shiraz, Iran. Hauptthemen laut MEDLINE: Heart Failure, Valsartan, Aminobutyrates, Tachycardia, Ventricular. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients with heart failure with reduced ejection fraction (HFrEF) frequently experience electrical disturbances, such as ventricular or atrial fibrillation (AF). Sacubitril/Valsartan (SV) therapy has been linked to lower rates of mortality, ventricular tachycardia (VT), and ventricular fibrillation (VF), with decreased reliance on implantable cardioverter‐defibrillator (ICD) therapy. However, studies on the antiarrhythmic effects of SV in patients with ICD or cardiac resynchronization therapy defibrillator (CRT‐D) devices are limited. This study aimed to evaluate the impact of SV therapy on antiarrhythmic pacing, defibrillation shock occurrences, and the burden of ventricular arrhythmias in patients with HFrEF who have ICD or CRT‐D devices.

Method

This study was conducted at a HF outpatient clinic involving patients with HFrEF treated with SV. Primary outcomes included the incidence of VT, VF, non‐sustained VT (NsVT), supraventricular tachycardia (SVT), and related interventions such as antiarrhythmic pacing (ATP) and defibrillation shocks.

Result

A total of 181 HFrEF patients completed at least 12 months of follow‐up, with a mean age of 63.39 ± 12 years; 36.5% were male, and 60.8% had an ICD. Device interrogation revealed a significant reduction in VF incidents (7 vs. 15, p = 0.025) and a decrease in the combined outcome of VT and VF (17 vs. 24, p = 0.047). The need for ICD interventions such as ATP and shocks also significantly decreased following the initiation of SV therapy (10 vs. 24, p = 0.012).

Conclusion

SV therapy significantly reduces the incidence of cardiac arrhythmias, particularly VT and VF, while decreasing the need for clinical interventions related to implanted devices.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureValsartanAminobutyratesTachycardia, VentricularTachycardia, SupraventricularAngiotensin Receptor AntagonistsVentricular FibrillationTetrazolesHumansMaleFemaleBiphenyl CompoundsDrug CombinationsMiddle AgedAgedDefibrillators, ImplantableTreatment OutcomeElectrocardiographyStroke VolumeArrhythmias, Cardiac

Stichwörter der Autor:innen

CRT‐DICDSacubitril/Valsartanarrhythmiasheart failure

Substanzen

Biphenyl CompoundsValsartansacubitril and valsartan sodium hydrate drug combinationAminobutyratesDrug CombinationsAngiotensin Receptor AntagonistsTetrazoles

Autor:innen und Institutionen

  • Department of Cardiology, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Cardiovascular Research Center, Department of Cardiovascular Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.
  • Student Research Committee, School of Medicine, Shiraz University of Medical Science, Shiraz, Iran.
  • Cardiac Primary Prevention Research Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Tehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.

ORCID-Profile: Majid Haghjoo, Shayan Shojaei, Roozbeh Narimani-Javid, Hamed Bazrafshan Drissi

Zitieren

APA

Arzhangzadeh, A., Nikoo, M. H., Haghjoo, M., Rasekh, F., Shojaei, S., Mousavi, A., Nozhat, S., Narimani-Javid, R., Bazroodi, H., Neisi, S., Mojibpour, M., Abedini, M., Eslamzadeh, S., Drissi, H. B., & Shafiei, S. (2025). The Effect of Sacubitril/Valsartan on Supraventricular and Ventricular Arrhythmias in Patients With Heart Failure. Annals of Noninvasive Electrocardiology. https://doi.org/10.1111/anec.70081

Vancouver

Arzhangzadeh A, Nikoo MH, Haghjoo M, Rasekh F, Shojaei S, Mousavi A, et al. The Effect of Sacubitril/Valsartan on Supraventricular and Ventricular Arrhythmias in Patients With Heart Failure. Annals of Noninvasive Electrocardiology. 2025. doi:10.1111/anec.70081

BibTeX
@article{Arzhangzadeh2025,
  author = {Arzhangzadeh, Alireza and Nikoo, Mohammad Hossein and Haghjoo, Majid and Rasekh, Fatemeh and Shojaei, Shayan and Mousavi, Asma and Nozhat, Salma and Narimani-Javid, Roozbeh and Bazroodi, Helia and Neisi, Sana and Mojibpour, Mitra and Abedini, Mohammad and Eslamzadeh, Saghi and Drissi, Hamed Bazrafshan and Shafiei, Sasan},
  title = {The Effect of Sacubitril/Valsartan on Supraventricular and Ventricular Arrhythmias in Patients With Heart Failure},
  journal = {Annals of Noninvasive Electrocardiology},
  year = {2025},
  doi = {10.1111/anec.70081}
}
Kostenlos starten →